Abstract Library

#3073 The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study

Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,

Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,

#320 Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs

Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: De Martino M, Ducreux M, Dromain C, Duvillard P, Guigay J, Leboulleux S,

Keywords: everolimus, mTOR, RECIST, pancreas, neuroendocrine, tumor, proliferative index, predictor,

#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors

Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Fekih M, Baudin E, Ducreux M, Chougnet C, Leboulleux S,

Keywords: carcinoid tumor, neuroendocrine tumors, therapeutics, Somatostatin analogues, lung,